pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$SRPTSarepta Therapeutics, Inc.

$SRPT15.13-5.85%
Cambridge, MA, USupdated 21h ago

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
4
phase 3
0
catalysts ytd
6
approvals ytd
1
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Marketed: 4Unknown: 1
4Marketed1Unknown
Marketed
casimersen
Duchenne Muscular Dystrophy
Marketed
delandistrogene moxeparvovec
Duchenne Muscular Dystrophy
Marketed
eteplirsen
Duchenne Muscular Dystrophy
Marketed
golodirsen
Duchenne Muscular Dystrophy
Dystrophin pre-mRNA
drug
AMONDYS 45
1 INDICATIONS AND USAGE AMONDYS 45 is indicated for the t…
Dystrophin pre-mRNA

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (2)
Nov 5, 2026
earnings
$SRPT15.13-5.85%
12d ago
Sarepta Therapeutics, Inc. earnings
Sarepta Therapeutics, Inc.
→
Nov 4, 2026
earnings
$SRPT15.13-5.85%
13d ago
Sarepta Therapeutics, Inc. earnings
Sarepta Therapeutics, Inc.
→
view all catalysts →

Active trials

  • phase1A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)terminatedn=2
  • —An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophyenrolling by invitationn=500
  • phase2Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophyrecruitingn=78
  • phase2Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1recruitingn=60
  • phase4Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Settingnot yet recruitingn=20
  • phase1A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Diseasenot yet recruitingn=32
  • phase1A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)recruitingn=83
  • phase3A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4active not recruitingn=17
🐶 Hiring Signal
No open roles indexed yet — view Sarepta Therapeutics, Inc. jobs →

News

  • Sarepta’s new CEO confident in clinical execution as DMD competitors close in
    Sarepta Therapeutics’ newly minted CEO Michael Severino laid out his path to returning the muscular dystrophy therapy maker to the forefront of the rapidly expanding market.
    biospace · 11d ago
  • BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
    If approved, BridgeBio Pharma’s BBP-418—which, according to one Jefferies analyst, boasts “pretty darn compelling” data—would be the first therapy for limb-girdle muscular dystrophy. The FDA has an…
    biospace · 15d ago
  • ‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban
    Since his release from prison in 2022, Martin Shkreli has traded stocks and publicly opined on news events, damaging reputations and sinking share prices for small biotechs including Capricor and C…
    biospace · 1mo ago
  • Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
    New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…
    biospace · 1mo ago
  • Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
    Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week sho…
    biospace · 1mo ago
  • Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
    The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
    biopharma_dive · 3mo ago
  • Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
    The FDA published briefing documents ahead of advisory committee meetings for therapies from Capricor Therapeutics and Replimune indicate an uphill battle for the biotechs; GSK and AstraZeneca outl…
    biospace · 3mo ago
  • Sarepta names former AbbVie R&D exec Michael Severino as next CEO
    After leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.
    biospace · 3mo ago
  • STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive
    The beleaguered Sarepta Therapeutics named Michael Severino, who previously led Tessera Therapeutics, as its new CEO.
    stat · 3mo ago
  • Building a workforce engine for biomanufacturing
    Ohio’s $30M training initiative aims to scale talent pipelines and power life sciences growth statewide.
    fiercebiotech · 4mo ago
view all news mentions →
identifiers
ticker
$SRPT
SEC CIK
0000873303
country
US
source
sec_tickers
top tags
Duchenne Muscular Dystrophy4
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 47m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?